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AbstrACt
Introduction Early intervention programmes (EIPs) for 
infants with neurodevelopmental impairment have been 
poorly studied especially in low-income settings. We aim 
to evaluate the feasibility and acceptability of a group 
participatory EIP, the ‘ABAaNA EIP’, for young children with 
neurodevelopmental impairment in Uganda.
Methods and analysis We will conduct a pilot feasibility, 
single-blinded, randomised controlled trial comparing the 
EIP with standard care across two study sites (one urban, 
one rural) in central Uganda. Eligible infants (n=126, 
age 6–11 completed months) with neurodevelopmental 
impairment (defined as a developmental quotient <70 
on Griffiths Scales of Mental Development, and, or 
Hammersmith Infant Neurological Examination score 
<60) will be recruited and randomised to the intervention 
or standard care arm. Intervention arm families will receive 
the 10-modular, peer-facilitated, participatory, community-
based programme over 6 months. Recruited families will 
be followed up at 6 and 12 months after recruitment, 
and assessors will be blinded to the trial allocation. The 
primary hypothesis is that the ABAaNA EIP is feasible and 
acceptable when compared with standard care. Primary 
outcomes of interest are feasibility (number recruited 
and randomised at baseline) and acceptability (protocol 
violation of arm allocation and number of sessions 
attended) and family and child quality of life. Guided by the 
study aim, the qualitative data analysis will use a data-led 
thematic framework approach. The findings will inform 
scalability and sustainability of the programme.
Ethics and dissemination The trial protocol has 
been approved by the relevant Ugandan and UK ethics 
committees. Recruited families will give written informed 
consent and we will follow international codes for ethics 
and good clinical practice. Dissemination will be through 
peer-reviewed publications, conference presentations and 
public engagement.
trial registration number ISRCTN44380971; protocol 
version 3.0, 19th February 2018.
IntroduCtIon
Globally each year, an estimated 30 million 
neonates experience complications around 
the time of birth which can have a life-long 
impact on health and development.1 The 
United Nations Global Strategy for Women’s, 
Children’s and Adolescents’ Health (2016–
2030) advocates the need for all children 
to ‘survive’ and to ‘thrive’.1 While in recent 
decades substantial progress has been made 
in reducing child mortality in low-income and 
middle-income countries (LMICs), the global 
burden of developmental disabilities remains 
unchanged.2 Child neurodevelopmental 
impairment (NDI) significantly impacts fami-
lies in any context, but particularly in low-re-
source settings, where availability and access to 
support services are limited, financial barriers 
greater and social stigma more overt.3
strengths and limitations of this study
 ► This pilot feasibility trial is among the first to examine 
feasibility and acceptability of an early intervention 
programme for young children with neurodevelop-
mental impairment in a low-resource sub-Saharan 
African setting.
 ► The mixed-method evaluation of this complex com-
munity-level intervention will provide important in-
formation on implementation of an early intervention 
programme for child disability at scale.
 ► While the small sample size and individually ran-
domised trial design will limit our understanding of 
programme impact, quantitative and qualitative data 
will inform design and execution of a larger future 
trial to examine effects on important child and family 
outcomes.
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A wide spectrum of impairment is seen after newborn 
illnesses, including cerebral palsy, ineffective feeding, 
learning, visual and hearing difficulties and epilepsy.4 A 
growing evidence base, largely from high-income coun-
tries (HICs), suggests that early intervention programmes 
(EIPs) commencing in the first months after birth have 
the potential to limit and even prevent developmental 
and cognitive impairments following early brain injury. 
These programmes target the neuroplasticity of the 
immature developing brain, either directly or indirectly, 
through family capacity building and enrichment of the 
care-giving environment.5
In HICs, it has been shown that early environmental 
enrichment can enhance motor function in children<2 
years.4 6 In LMICs, several trials have shown positive 
effects of EIPs in at-risk infants,7–10 although these studies 
have not focused on infants specifically with NDI. Few 
studies have examined the feasibility and acceptability 
on affected children and their caregivers, and how they 
might be integrated into existing community health 
programmes.11 Scalability and sustainability of an inter-
vention programme are also dependent on its cost effec-
tiveness. This is particularly true in LMICs where resources 
are scarce and existing care structures for children much 
less well established.
Aims
The study aims to evaluate whether a facilitated, commu-
nity-based, participatory EIP is feasible and accept-
able. We will conduct a pilot feasibility single-blind, 
randomised controlled trial (RCT) with two parallel 
groups. The outcomes of interest are feasibility of rando-
misation and recruitment, acceptability among caregivers 
and healthcare workers and early evidence of family 
impact quality of life (QoL), 6 months after recruitment 
and again 6 months later. The incremental and protective 
cost effectiveness of the EIP and the economic impact of 
child developmental disability to families and services in 
Uganda will be examined by Katumba et al in a separate 
protocol.
objectives and hypotheses
The primary objectives of the study are to
1. Describe the feasibility and acceptability of the EIP for 
children with NDI and their families.
Hypothesis: It will be feasible to conduct an RCT of the EIP 
versus standard care (SC) in rural and urban contexts and 
acceptable to families and the community.
2. Obtain preliminary data on whether the EIP improves 
family QoL when compared with SC.
Hypothesis: Families receiving the community-based EIP will 
demonstrate improved QoL scores on the Paediatric Quality 
of Life Family Impact module compared with SC 12 months 
after recruitment.
3. Identify the main barriers and facilitating factors for 
scaling up the EIP.
Hypothesis: The EIP is scalable in this low-resource Ugandan 
setting.
4. Determine the incremental and protective cost effec-
tiveness of the ABAaNA EIP.
Hypothesis: The ABAaNA EIP is a cost-effective intervention 
to improve family QoL for children with NDI.
MEthods
We will conduct a pilot feasibility, single-blind, RCT with 
two parallel groups: one receiving the EIP and the other 
SC.
study setting
The study is based at two Ugandan sites: one urban 
(Mulago Hospital, Kampala) and one rural (Kiwoko 
Hospital, Nakaseke). Neither site has existing family 
support services for children with NDI.
Mulago National Referral Hospital is the largest in 
Kampala, Uganda’s capital city, taking high-risk pregnan-
cies from across surrounding areas. Children’s services 
include acute admissions, an inpatient malnutrition unit 
and outpatients, with a weekly paediatric neurology clinic 
providing investigation and management of neurological 
conditions including seizures, and a clinic-based physio-
therapy and occupational therapy service for children 
with cerebral palsy and other NDIs.
Kiwoko Hospital in Nakaseke District, central Uganda, 
serves a catchment area of 800 000 people and provides 
comprehensive medical services, including neonatal 
inpatient care for >1200 infants per year. The trial imple-
mentation partner, Adara Development, has worked in 
partnership with Kiwoko Hospital since 1998, and the 
government to improve neonatal health in Nakaseke 
district. Together they provide HIV services, maternal 
health services and community-based healthcare to 44 
villages surrounding Kiwoko Hospital.
Participants and recruitment
Participants will be young children with NDI and their 
caregivers. A Standard Protocol Items: Recommendations 
for Interventional Trials diagram showing the planned 
flow of participants is presented in figure 1.
Screening for eligibility
Infants at high-risk of NDI will be identified from (1) 
neonatal admission registers and neonatal follow-up 
services, (2) local paediatric outpatient services and (3) 
attendance for early child health services following commu-
nity sensitisation. Sensitisation will include public health 
announcements on local radio raising awareness of the 
research and appropriate child development more gener-
ally. Caregivers of high-risk infants (survivors of neonatal 
encephalopathy, prematurity, neonatal septicaemias/
meningitis and severe jaundice) will be contacted by phone 
and invited to attend an appointment when the child 
is 6–11 completed months old. After informed written 
consent, they will be screened for NDI by trained study 
staff using the Malawi Developmental Assessment Tool 
(MDAT).12 If two or more items in any MDAT domain are 
not achieved, the child will be referred for comprehensive 
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Figure 1 Flow of participants. *In-depth interviews (IDI) with caregivers on impact of disability, confidence level of the parents, 
level of participation in family and community life and experience of stigma/discrimination. EIP, early intervention programme; 
GMDS, Griffiths Mental Developmental Scales; HINE, Hammersmith Infant Neurological Examination; HOME, Home Observation 
for the Measurement of the Environment; MDAT, Malawi Developmental Assessment Tool; MIRI, Maternal Infant Responsiveness 
Inventory; NDI, neurodevelopmental impairment; PedQL, Pediatric Quality of Life tool; PEDI, Pediatric Evaluation Disability 
Inventory; PSI, Parent Stress Index; SRQ, Self-Referral Questionnaire.
neurodevelopmental assessment. If the child fails one item 
in two or more domains, they will be invited back for an 
assessment in 1 month. If the child’s MDAT scores are age 
appropriate across all domains, advice will be given on play 
and stimulation, communication, nutrition and immunisa-
tions and the child discharged.
Caregivers of infants screening positive on MDAT 
will be invited to an appointment for written informed 
consent, and if provided, comprehensive neurodevelop-
mental assessment by study staff using the Griffiths Mental 
Developmental Scales (GMDS)13 and the Hammersmith 
Infant Neurological Examination (HINE).14 An overall 
developmental quotient will be derived, from the GMDS 
subscales assessing locomotor, personal–social, hearing/
language, eye-hand coordination and performance 
skills.13 Neuromotor impairment will be further assessed 
according to the HINE, a standardised paediatric neuro-
logical examination and classified by type. We have used 
both these tests extensively in previous studies in Uganda 
and found them easy to administer in this setting and at 
this age.15 The assessments will be conducted in the local 
language using the standard manual material to ensure 
internal consistency in the assessments technique. Inclu-
sion and exclusion criteria are outlined in box 1.
baseline characteristics
Infant and caregiver demographic information will be 
recorded at baseline, including date of birth, age, sex, 
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box 1 Eligibility for inclusion in the randomised 
controlled trial
Inclusion criteria
 ► Infant aged 6–11 completed months
 ► Moderate–severe neurodevelopmental impairment (NDI) defined 
as a Griffiths Mental Developmental Scales (GMDS) Developmental 
Quotient <70 and/or Hammersmith Infant Neurological Examination 
(HINE) score <60 (Romeo, 2013)
 ► Informed written consent by caregiver
Exclusion criteria
 ► Infants aged 12 months of age or older
 ► Infants screening positive for NDI (using Malawi Developmental 
Assessment Tool) but not meeting the criteria for moderate–severe 
NDI on GMDC and HINE assessment
 ► Conditions requiring prolonged inpatient treatment
 ► Parents unwilling or unable to attend the full programme
 ► Main residence outside Nakaseke or Luwero district, and >20 km 
from Mulago Hospital
 ► Accompanying caregiver not speaking or understanding Luganda 
or English
box 2 developing the AbAanA early intervention 
programme (EIP)
 ► In low-income and middle-income countries, services for affected 
children are often lacking and parental levels of knowledge and un-
derstanding about cerebral palsy are often low. To fill this gap, a 
parent training programme called ‘Getting to Know Cerebral Palsy’ 
was developed and launched in partnership between the London 
School of Hygiene & Tropical Medicine and Christian Blind Mission 
an international disability and development organisation. The pro-
gramme aims to increase parental knowledge and skills and pro-
motes a participatory learning approach with an emphasis on the 
empowerment of caregivers across a broad spectrum of impairment 
for children aged 2–12 years.23 24
 ► Since 2011, the ABAaNA studies (‘Abaana’, meaning ‘children’ in the 
local language Luganda) have been examining risk factors for, and 
outcomes from, neonatal encephalopathy (NE) in Uganda.15 Studies 
examining early neurodevelopmental outcomes after NE revealed a 
high prevalence of neurodevelopmental impairment (NDI) with 25% 
of those affected also having malnutrition from related feeding diffi-
culties.15 Qualitative work highlighted the stigma and broad-ranging 
social, emotional and financial impacts on affected families.3
 ► In response, the ABAaNA EIP was developed around the principles of 
‘Getting to Know Cerebral Palsy’ (http://www.ubuntu-hub.org), and 
has been adapted for younger children aged 0–2 years following an 
iterative process following Medical Research Council recommenda-
tions on development and evaluation of complex interventions25; it 
was supported by a diverse Expert Advisory Group including local 
parents with children with NDI, Disabled Persons Organisations and 
experts in early intervention and child development. Core themes 
running through the programme are summarised in figure 2. The 
newly developed programme was piloted among 28 families at 
Mulago Hospital in Kampala in 2015–2016 and showed a 25% 
improvement in family quality of life scores (Paediatric Quality 
of Life tool, Family Impact module 2.0) post intervention (verbal 
communication).
birth order, parity, antepartum, intrapartum and post-
partum history, family and medical history, developmental 
history, mother’s education and occupation, family details 
including family size, and ages, household incomes, 
household SES and residence. All outcome measures will 
also be measured at baseline enabling preintervention 
and postintervention comparisons.
randomisation
Infants and their caregivers will be randomised in a 1:1 
ratio to either the EIP or SC arm. Randomisation will 
be stratified by recruitment centre. Randomisation lists 
indicating a randomisation number and trial arm allo-
cation will be prepared by the trial statistician using a 
random number generator in Stata (V.15) prior to the 
commencement of the study, and stored on a secure, 
password-protected computer at the Medical Research 
Council/Uganda Virus Research Institute (MRC/UVRI) 
and London School of Hygiene & Tropical Medicine 
(LSHTM) Uganda Research Unit by a statistician other-
wise not involved in the study. When a participant is 
eligible for recruitment and consent obtained, study staff 
will contact the MRC/UVRI statistician who will inform 
the study staff of the study number and trial arm to which 
the participant is to be allocated. The personnel in charge 
of the randomisation will not be involved in other study 
procedures, including assessment of outcomes.
Intervention arm
The EIP is a community-based, peer-led group 
programme with caregivers at a community level, using a 
participatory approach driven by adult learning theory.16 
The programme manual is freely available to download 
(https://www. ubuntu- hub. org). Development of the 
programme is described in box 2.
Participating families are encouraged to share experi-
ences through discussion and reflection, prioritise prob-
lems and identify solutions together. Facilitators of the 
group sessions are ‘expert parents’, themselves parents 
of children with NDI, who have undergone 5 days of 
core training followed by regular supervision, face-to-
face mentoring meetings and telephone discussions with 
existing in-country master facilitators (trained therapists 
in Uganda). Each EIP group involves 6–10 families; groups 
are selected depending on locality for ease of attendance. 
The training is divided into 10 modules covering under-
standing disability, positioning and carrying, feeding, 
mobilising, communication, play, everyday activities and 
experiences in the local community (figure 2, table 1). 
Individual module sessions are delivered every 1–2 weeks 
and last 2–3 hours including time for facilitated discus-
sion; the entire programme is designed to be delivered 
over 6 months including at least one home visit conducted 
by the expert parent facilitator.
Fidelity and adherence to the intervention
EIP facilitators will receive a 5-day training programme 
delivered by two master facilitators, which includes 
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Figure 2 Core themes and content of the ABAaNA early intervention programme.
facilitation skills, knowledge transfer on the core contents 
of the EIP manual and translation of knowledge to prac-
tice through simulated sessions with families and children 
with NDI. All trial intervention groups will be co-facilitated 
by a master facilitator providing supportive supervision 
to new facilitators. After each modular group meeting, a 
short-facilitated feedback session will be conducted, and 
the content of the module delivered will be recorded. 
Attendance of individual caregivers and children at the 
group sessions will be recorded. Facilitators will empha-
sise to caregivers the importance of attending all sessions, 
with phone calls prior to each session to promote adher-
ence. If missed, a catch-up session may be offered before 
the next module.
standard care arm
SC refers to care that is currently available in established 
local services. In both sites, this includes referral to phys-
iotherapy, seizure management and nutritional support. 
Information on access to local medical, therapy and family 
services will be collected. Families in the SC arm will be 
offered delayed entry into the EIP after completing the 
18-month assessment. Contamination of the SC arm by 
exposure of SC families to intervention will be monitored 
and reported.
outcomes
Participants in both arms will be assessed by study staff 
masked to trial allocation at two time points; at age 12–17 
months (which corresponds to completion of the EIP in 
the intervention arm, 6 months after recruitment) and 
again at age 18–23 months (12 months after recruit-
ment). (figure 1). Caregivers will be phoned a week 
before the follow-up assessments to arrange a time for 
interview. Assessments will be primarily conducted in the 
study-site clinics. Where caregivers cannot be contacted 
by phone or are unable to attend the clinic, a commu-
nity visit will be arranged, and assessments completed 
at home. Outcome assessments will be conducted by 
Mulago assessors for children recruited at Kiwoko, and 
vice versa to ensure assessors are blind to allocation arm. 
Two assessors will independently assess a small propor-
tion of the children and inter-rater reliability will be 
calculated.
Primary outcome measures
The primary outcomes of the study will be:
1. Feasibility of participant recruitment and randomisation as 
assessed by the total number recruited and randomised 
to each arm. Qualitative tools will also be used to cap-
ture information on feasibility.
2. Acceptability of the EIP among caregivers and healthcare work-
ers as assessed by the protocol violation rate (eg, partic-
ipants in the intervention arm being treated as if they 
were in the control arm or vice versa) at programme 
completion, and by the number of programme ses-
sions attended between baseline and programme com-
pletion. Qualitative tools will also be used to capture 
information on acceptability.
3. Preliminary evidence of impact on family QoL as assessed 
using the scored Paediatric Quality of Life (PedsQL) 
Family Impact module.17 The PedsQL comprises 36 
items scored on a 0–4 Likert scale and linearly trans-
formed to a 0–100 scale, with higher scores indicating 
a better QoL. It will be translated into the local lan-
guage Luganda and administered as a standardised 
structured interview by trained study staff.
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Table 1 Description of the programme modules
Module Content
1.Let’s get started Content and ground rules of the 
programme
Understanding cerebral palsy, 
additional resources for information
Personal stories
2.Know your child Developmental milestones for young 
children
Determining each child’s progress
3.Positioning and 
carrying
The importance of optimal positioning
Practical skills regarding optimal 
positioning
4.Eating and drinking Feeding challenges for children with 
neurodevelopmental impairment
Practical skills for addressing feeding 
challenges
5.Learning to move Understanding different types of 
movement
Practical skills for assisting learning 
to move
6.Communicating The importance of communication
Practical advice to encourage their 
child to communicate
7.Play and early 
stimulation
The importance of early stimulation 
and play for children to develop
Challenges of inclusion in play with 
the family and community
Creation of simple toys
How parents/ caregivers can 
encourage their child to play
8.Everyday activities Using everyday activities to promote 
child development
Management of seizures
Review of previous sessions
9.Our community Community resources available
Discussion around barriers to 
inclusion, addressing stigma and 
discrimination
Understanding disability rights
Thoughts and feelings of the 
caregiver
Members of community invited to 
attend this session
10.Next steps Planning to facilitate their own group
Reflection on learning points
Endpoint data collection
Other outcomes of interest
1. Child motor functioning as assessed by the mobility 
score of the Paediatric Evaluation Disability Inventory 
(PEDI).18 The PEDI is a standardised test designed to 
identify and describe functional impairment and mon-
itor progress. Normative scaled scores are obtained for 
children≥6 months to provide age-related expectations 
of ability.
2. Child cognitive function as assessed by the GMDS.13
3. Child growth, health and well-being assessed using weight, 
height and head circumference measured according 
to standardised protocol. Occipitofrontal head cir-
cumference (paper tape measure), weight (SECA336 
electronic scales, Hamburg, Germany) and height 
will be taken by study staff using standardised proce-
dures. Haemoglobin will be determined on a finger 
prick sample using HemoCue Hb 201 (HemoCue AB, 
Angelholm, Sweden). A structured maternal interview 
in Luganda will report on caregivers concerns regard-
ing health, growth and development of their child and 
episodes of illness including seizures and other neuro-
logical problems, feeding difficulties, chest infections 
and treatment for malnutrition.
4. Caregiver psychological distress assessed using the Self-Re-
ferral Questionnaire (SRQ) and the Parenting Stress 
Index (PSI).19 The SRQ consists of 20 items each 
scored 0 (symptom absent) or 1 (symptom present) 
giving a total out of 20. The PSI is a 120-item inventory 
measuring the magnitude of caregiver stress attribut-
able to parent–child relationship (Total Stress Scale), 
and situational/demographics factors outside the par-
ent–child relationship (Life Stress Scale). These tools 
will be translated into Luganda.
5. Caregiver–child attachment assessed using the Maternal 
Infant Responsiveness Instrument; a 22-item scale de-
signed to measure the parent’s feelings about their in-
fant and an appraisal of the infant’s responses.20
6. Quality of the home environment assessed using the Infant 
Toddler-Home Observation for the Measurement of 
the Environment. This comprises 45 items, based on 
observation and/or interview, assessing the physical 
environment of the home and the child’s interaction 
within it.21
7. Cost of illness and protective effectiveness will be assessed 
(separate protocol, Katumba et al).
Qualitative methods
In-depth interviews (IDIs) will be conducted with five 
randomly selected caregivers from each arm at each 
site. Focus group discussions (FGDs) will be conducted 
with caregivers, at baseline, 6 months post recruitment 
and again 6 months later in both the intervention and 
SC arms. Among intervention arm families, qualitative 
techniques will be used to capture information on the 
feasibility, acceptability and impact of the EIP interven-
tion using qualitative tools including FGDs, IDIs and 
observation.
We will describe the experiences of children and care-
givers relating to the intervention received including the 
impact of the disability, parental confidence level, inclu-
sion in community life and experience of stigma and 
discrimination. We will examine changes in these domains 
over the follow-up period and explore attributions of 
change. In addition, we will perform social mapping 
of parent networks and group discussions with staff on 
their perspectives and experiences of using the EIP. The 
themes guiding our analysis will be drawn from objectives 
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of the trial and from the data, should additional areas of 
interest emerge during interviews and discussions.
The interviews will be conducted by social scientists 
who have experience in qualitative research.
data management and access
Data collected in the clinic or at field visits will be entered 
on standard clinical record forms (CRFs). Clinical data 
will be recorded under a unique study ID number. 
Completed CRFs will be checked by and double entered 
into a trial-specific MS Access database. Data from both 
IDIs and FGDs will be collected in the form of audio-
tapes, transcripts and field notes. All data entry and 
data management will be overseen by a statistician/data 
manager at the MRC/UVRI Unit. Data will be maintained 
on the host institution server and backed up following 
standardised operating procedures. Paper CRFs will be 
stored in lockable filing cabinets at the sites. Access to 
these data during the trial will be restricted to essential 
personnel (the principal investigators, site co-investiga-
tors, medical research officers and data clerks).
Confidentiality
All research team members will receive training in confi-
dentiality. Data will be stored without personal identifiers, 
except where names must be included to ensure identifi-
cation of the correct participants for procedures. All data 
will be stored on password-protected computers, acces-
sible only to research team members.
sample size
The trial will recruit 126 children and their caregivers, 63 
per arm. Allowing for a 20% dropout rate, this sample size 
will give 90% power to detect a minimal relative differ-
ence of 20% on PedQL Family Impact score between the 
intervention and control arms, at 5% significance level, 
assuming a mean PedQL score of 65 in the SC arm and 
SD of 20 in both arms. Assumptions are based on data 
from the pilot study showing a mean caregiver PedQL 
score for families before the intervention of 64.9 (SD 
19.6) and mean score of 78.9 for families after receiving 
the intervention (SD 17.5).
statistical analysis
The first primary outcome, feasibility of participant 
recruitment and randomisation, will be assessed by the 
total number recruited and randomised to each arm. 
Recruitment and randomisation feasibility will be demon-
strated if the target sample size of 126 is achieved. Data 
on participants screened, eligible and randomised will 
be displayed in a Consolidated Standards of Reporting 
Trials flow chart. Descriptive statistics (frequencies, 
means, medians, SD and IQRs) will be used to describe 
the sample at baseline, by trial arm.
The second primary outcome, acceptability, will be 
assessed quantitatively by (1) calculating the protocol 
violation rate and (2) summarising the number of 
programme sessions attended between baseline and 
programme completion for those in the intervention arm. 
Protocol violation rate will be calculated as the number of 
participants for whom one or more protocol violations 
occur divided by the total number of participants, and 
will be presented both overall, and by trial arm. For partic-
ipants in the EIP trial arm, the overall number of modules 
attended by each participant will be tabulated. Accept-
ability on the basis of number of programme sessions will 
be defined as attendance of at least six modules.
For the third primary outcome and secondary outcomes, 
analyses will compare outcomes between intervention 
and control arms at the end of the programme, when 
the participants will be aged 12–17 months, and again 
6 months later. Analysis will be on an intention-to-treat 
basis and missing data will not be imputed. Data for each 
outcome measure will be summarised by trial arm, using 
proportions for binary outcomes and means or medians 
for quantitative outcomes, depending on normality of the 
distribution. Differences in means/proportions between 
trial arms together with 95% CIs will be calculated. We 
do not plan any formal statistical tests due to the prelimi-
nary nature of the trial; instead CIs will provide a possible 
range of effect sizes. Regression models (linear regression 
for continuous outcomes, logistic regression for binary 
outcomes) will be used to adjust comparisons for baseline 
measures of the outcomes, which were collected at enrol-
ment into the trial, in order to improve precision of effec-
tiveness estimates. For skewed continuous outcomes, data 
will be normalised before analysis using suitable trans-
formations or quantile regression will be considered. No 
subgroup analyses are planned.
Qualitative data will be analysed using a thematic 
framework approach. Themes will be based on the study 
objectives and those emerging from the data. Social scien-
tists (two people) will agree the coding frame and under-
take analysis collaboratively to ensure agreement on the 
coding approach. Thematic summaries will be developed 
and shared with the wider team for discussion.
trial management, data monitoring and reporting of adverse 
events
The Trial Steering Committee (TSC)22 will oversee prog-
ress of the study towards its objectives, review relevant 
information from other sources (eg, other related trials) 
and receive reports from the Data and Safety Monitoring 
Board (DSMB). All adverse events, whether related to 
the intervention or not, will be noted and reported. A 
Data Monitoring and Safety Committee has been estab-
lished independent of the investigators and the TSC 
but reporting to the TSC and the sponsor. The DSMB 
includes an expert on global child heath, a senior stat-
istician and a senior academic working in newborn and 
early child health research in Uganda, independent of 
the investigators. The DSMB will have access to all data on 
request. Resulting from the initial meeting of the DSMB 
on 28 June 2017, no formal stopping rules will be applied.
Children with NDI and particularly those with seizure 
disorders and difficulties with swallowing are at increased 
mortality risk. All adverse events, whether related to the 
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intervention or not, will be investigated and reported 
according to the UVRI Research Ethics Committee (REC) 
in accordance with good clinical practice requirements. 
All deaths, hospitalisations and other serious adverse 
effects will be reported to the relevant ethics committee 
irrespective of whether the death or event is related to 
disease progression or not. Trial data monitoring will be 
conducted by an internal independent monitor at initia-
tion, 6 months into data collection, again after 1 year and 
end of data collection.
PArtICIPAnt And PublIC InvolvEMEnt
The intervention, study design and conduct were devel-
oped directly from the engagement of caregivers and 
programme facilitators (‘expert parents’) with a parent 
representative on the TSC. The priorities and experi-
ences of caregivers identified during facilitated group 
discussions at a key-stakeholders meeting (June 2017) 
contributed to the development of our research question 
and outcome measures. Plans to communicate findings 
to participants and the wider community will involve care-
givers, through formal discussions with the TSC.
EthICs And dIssEMInAtIon
Ethics
The protocol has been approved by the Research and 
Ethics committee of the UVRI, Mulago Hospital and 
Kiwoko Hospitals, the Uganda National Council for 
Science and Technology, the Uganda President’s Office, 
and the ethics committee of the LSHTM. Information 
sheets will be available in English and Luganda, the main 
local language. Parents will be provided with an oral and 
written explanation of the study by Ugandan study staff to 
ensure that information is accessible to those with lower 
levels of literacy. Witnessed consent using a thumb print 
will be available to parents/guardians who are non-lit-
erate. Reimbursement for the cost of transport will be 
provided to caregivers on attendance at the screening 
and recruitment visits.
All recruited children will receive SC at the study sites. 
This will include referral to local services for seizure 
management and physiotherapy where available. To date, 
the benefits of the proposed EIP have not been proven 
and may have a negative effect if children are incorrectly 
classified as having NDI and placed in the programme. 
Children and their caregivers in the control arm will 
receive delayed entry into the programme for older chil-
dren (‘Getting to Know Cerebral Palsy’) at 18–23 months 
at the time of their final study assessments.
dissemination
Our programme has strong links with partnership organ-
isations working in Maternal and Child Health program-
ming including Adara Development, Kiwoko Hospital, 
Nakaseke District Health Office and other collaborating 
institutions. Research findings will be disseminated to the 
Ministry of Health, to inform local and national health 
policies. Regional-level stakeholders, including the 
Nakaseke District Health Office and heads of regional 
health and social services, will be engaged to support 
staff recruitment, contributing to the sustainability of the 
innovation at local and district levels. Meetings for key 
stakeholders, including local Non-Governmental Organ-
isations working in child disability will be held twice 
during the project period to promote buy-in, facilitate 
fast-cycle learning, disseminate study findings and ulti-
mately promote sustainability of the programme. Global 
learning will be facilitated through our existing online 
community of practice spanning 70 countries and >300 
members. Communications support staff at MRC/UVRI, 
LSHTM and Adara Development will facilitate dissemina-
tion of information through appropriate media outlets, 
the web and social media.
Study findings will be published through Open Access 
peer-reviewed journals, presentations at local, national 
and international conferences and to the local commu-
nity through community meetings. Written reports will be 
submitted to UVRI REC and reported to the trial registry. 
Data will be made available on request.
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